SCHEMBL517795

SCHEMBL517795

O=C(O)C1=C(C(=O)N(F)c2c(F)cc(-c3cccc(OC(F)(F)F)c3)c(F)c2F)C(O)CC1

nearest known ligand 0.43

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 19/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4399442 0.93 DHODH (0.43) DHODH
SCHEMBL517490 0.85 DHODH (0.55) DHODH
SCHEMBL299934 0.83 DHODH (0.55) DHODH
SCHEMBL517020 0.78 DHODH (0.58) DHODH
SCHEMBL517921 0.74 DHODH (0.53) DHODH
SCHEMBL299773 0.72 DHODH (0.72) DHODH
SCHEMBL4399438 0.69 DHODH (0.74) DHODH
SCHEMBL17242642 0.66 DHODH (0.61) DHODH
SCHEMBL6246502 0.65 DHODH (0.52) DHODH
SCHEMBL14423001 0.64 DHODH (0.68) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015154820-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS PANOPTES PHARMA GMBH (AT) 2015-10-15 WO claimed
US-8354433-B2 Anti-inflammatory agents as virostatic compounds 4SC AG (DE) 2013-01-15 US claimed
EP-2427186-B1 DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS PANOPTES PHARMA GES M B H (AT) 2022-01-12 EP disclosed
US-9795590-B2 Anti-inflammatory agents as virostatic compounds PANOPTES PHARMA GMBH (AT) 2017-10-24 US disclosed
US-20170027905-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS Panoptes Hparma GmbH (AT) 2017-02-02 US disclosed
US-8354433-B2 Anti-inflammatory agents as virostatic compounds 4SC AG (DE) 2013-01-15 US disclosed
US-20120028985-A1 COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE 4SC AG (DE) 2012-02-02 US disclosed
EP-2362771-A1 COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE 4SC AG (DE) 2011-09-07 EP disclosed
US-20100280081-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS 4SC AG (DE) 2010-11-04 US disclosed
WO-2010052027-A1 COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE 4SC AG (DE) 2010-05-14 WO disclosed
EP-1581477-B1 CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2009-12-02 EP disclosed
US-20070224672-A1 Method of Identifying Inhibitors of DHODH LEBAN JOHANN 2007-09-27 US disclosed
US-7247736-B2 Method of identifying inhibitors of DHODH 4SC AG (DE) 2007-07-24 US disclosed
US-20070027193-A1 Method of identifying inhibitors of DHODH 4SC AG (DE) 2007-02-01 US disclosed
US-7071355-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4 SC AG (DE) 2006-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027193-A1 Method of identifying inhibitors of DHODH DHODH, SQOR, NDUFA5 DHODH 1/4885
US-20120028985-A1 COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE HLA-DRB1, IL2, SSB DHODH 2305/4885
US-20170027905-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS TNF, RPL35, NFKBIA DHODH 2832/4885
US-20100280081-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS TNF, MIF, IL1B DHODH 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.